Company: HROW
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022980
Chunk: 61

Company: HARROW, INC.
Filing Date: 2025-08-11
Form: 10-Q
Item: Item 1
Chunk 61
---
 unaudited condensed consolidated financial statements included in this Quarterly Report) during
2025 and to refinance the 2026 Notes (as defined in Note 10 of our unaudited condensed consolidated financial statements included in
this Quarterly Report) at the same time or soon thereafter. Management believes it is probable that we will be able to refinance the
Oaktree Loan and 2026 Notes; however, there can be no assurance that we will obtain the refinancing on terms acceptable to us, or at
all - see the subheading Sources of Capital below for additional discussion regarding the Oaktree Loan, 2026 Notes and refinancing
plans. In addition, we may consider the sale of certain assets. However, we may pursue acquisitions of products, drug candidates or other
strategic transactions that involve large expenditures or we may experience growth more rapidly or on a larger scale than we expect,
any of which could result in the depletion of capital resources more rapidly than anticipated and could require us to seek additional
financing to support our operations.

We
expect to use our current cash position and funds generated from our operations and any financing to pursue our business plan, which
includes developing and commercializing drug candidates, compounded formulations and technologies, integrating and developing our operations,
pursuing potential future strategic transactions as opportunities arise, including potential acquisitions of additional drug products,
drug candidates, and/or assets or technologies, pharmacies, outsourcing facilities, drug company and manufacturers, and otherwise fund
our operations. We may also use our resources to conduct clinical trials or other studies in support of our formulations or any drug
candidate for which we pursue FDA approval, to pursue additional development programs or to explore other development opportunities.

Net
Cash Flow

The
following provides detailed information about our net cash flows for the six months ended June 30, 2025 and 2024:

    For the Six Months Ended June 30, 

    2025  
    2024 
  
    Net cash provided by (used in): 

    Operating activities 
    $18,865,000  
    $(7,374,000)
  
    Investing activities 
     (505,000) 
     4,993,000 
  
    Financing activities 
     (12,644,000) 
     (736,000)
  
    Net change in cash and cash equivalents 
     5,716,000  
     (3,117,000)
  
    Cash and cash equivalents at beginning